15.20
+1.88%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Santhera Pharmaceuticals Holding
Its shares trade on SIX under the ticker SANN.SW. It has been listed since 3 November 2006. In the fiscal year to 31 December 2025, it reported revenue of CHF 77.2m and a net loss of CHF 49.2m. At that date it held total assets of CHF 148.1m and shareholders' equity of −CHF 11.8m.
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Nov 2006
- Employees
- 112
- Website
- santhera.com ↗
Leadership
Pay as last reported
- Dr. Thomas MeierNon-Executive Independent Chairman of the Board, since 2004CHF 200,000
- Mr. Dario EklundChief Executive Officer, Member of the Executive Management BoardCHF 2.0m
- Ms. Catherine IstedChief Financial Officer, Member of the Executive Management Board
- Mr. Marc SchraderChief Technology Officer
- Mr. Oliver StrubHead of Compliance
- Mr. Geert- Jan van DaalChief Commercial Officer
- Dr. Oliver KronenbergChief Legal Officer, Corporate Secretary, Member of the Executive Management Board
- Mr. Shabir HashamChief Medical Officer and Member of the Executive Management Board
- Mr. Philipp GutzwillerNon-Executive Independent DirectorCHF 145,000
- Mr. Bradley MeyerNon-Executive Independent DirectorCHF 168,750
- Dr. Otto SchwarzNon-Executive Independent DirectorCHF 143,750
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 28
- Social
- 20
- Governance
- 28
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Santhera Pharmaceuticals has 112 employees focused on neuromuscular disease treatments.
- Catena and Raxone brands target Leber's Hereditary Optic Neuropathy (LHON) diseases effectively.
- Santhera operates through subsidiaries in Switzerland, USA, Canada, Germany, and Finland.
Weaknesses
- Santhera's IPO date was 3 November 2006, which is over 17 years ago.
- The company's products are limited to neuromuscular and mitochondrial diseases.
- Santhera's headquarters city is Pratteln, Basel-Landschaft, which may limit market reach.
Opportunities
- Santhera's subsidiaries in the USA and Canada offer expansion potential in North America.
- The growing focus on mitochondrial diseases presents new market opportunities.
- Raxone's use in LHON treatment could attract more patients globally.
Threats
- Santhera's reliance on a single product line for neuromuscular diseases poses a risk.
- The company's small size with 112 employees may hinder rapid growth.
- Santhera's limited presence in emerging markets like Asia could be a challenge.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.